Back to Technologies
We license the CTP intellectual property necessary to develop CTP-based drug candidates from Washington University of St. Louis pursuant to a License Agreement. The License Agreement is exclusive for human therapeutics, with the right to sub-license, for all therapeutic proteins and peptides, of natural or non-natural sequence, other than four endocrine proteins - LH, FSH, TSH and hCG, previously licensed to Merck & Co., a leading pharmaceutical company.
In addition, we have been issued by the U.S. Patent Office the following CTP-related patents:
We also license intellectual property necessary to develop RevPEG drug candidates from the Weizmann Institute of Science (Israel) pursuant to a License Agreement.
We have filed several other patent applications covering our platforms and drug candidates in the U.S. and other territories.